Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Winner Medical Co., Ltd. (300888.SZ)
Shenzhen, CN
Winner Medical Co., Ltd., a subsidiary of Winner Group Limited, is a company dedicated to the entire lifecycle – from innovation and production to sales – of cotton-derived medical supplies and various consumer goods. Based in Shenzhen, China, its business primarily serves the Chinese market, yet its products reach customers in approximately 110 countries globally. The company's operations are distinctly segmented into Medical Consumables and Healthy Consumer Goods. Under the Medical Consumables umbrella, Winner Medical offers a comprehensive selection of wound care items, which include various gauze and non-woven dressings, bandages, complete dressing change kits, and advanced options like silicone and alginate dressings. This division also produces essential infection control products such as surgical kits, protective gowns, face masks, full-body protective clothing, isolation garments, gloves, and specialized footwear and headwear. Moreover, it supplies a range of disinfection and cleaning products, from cotton swabs, pads, and balls to alcohol wipes and general disinfectants. The Healthy Consumer Goods segment features its own line of non-woven fabric, alongside a broad array of finished non-woven consumer items like cotton facial tissues, wet wipes, feminine hygiene products, cotton buds, cosmetic pads, and disposable undergarments. This segment further extends to textile consumer products, offering everything from baby essentials and clothing to adult apparel and other fabric-based goods. These diverse product lines are marketed under the distinct brand names "Winner," "Purcotton," and "PureH2B." The company utilizes a multi-channel distribution strategy, engaging with pharmacy chains, hospitals, e-commerce platforms, and supermarkets to deliver its products. Winner Medical Co., Ltd. was founded in 1991.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | -1.01% | -6.51% | -17.95% | -25.67% | -22.57% | -39.44% | -30.12% | -70.33% | -67.51% | -67.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+22.0% ★ Q1'26: +2.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+10.9% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+6.5% ★ Q1'26: -13.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+10.1% Q1'26: +13.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+8.0% ★ Q1'26: +9.3% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.4% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.86× ★ Q1'26: 2.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.53B
est: 13.16B (-4.8%)
|
8.13B
est.
|
8.04B
est: 11.21B (-28.3%)
|
11.35B
est: 7.95B (+42.8%)
|
8.19B
est: 7.95B (+2.9%)
|
8.98B
est: 8.82B (+1.8%)
|
10.95B
est: 11.27B (-2.9%)
|
12.14B
11.85B – 12.39B
+7.7% YoY
|
13.47B
12.70B – 14.00B
+11.0% YoY
|
14.80B
14.73B – 14.86B
+9.8% YoY
|
| EBITDA |
4.67B
est: 2.58B (+80.8%)
|
1.59B
est.
|
1.66B
est: 2.20B (-24.5%)
|
2.24B
est: 1.35B (+65.7%)
|
1.13B
est: 1.35B (-16.4%)
|
1.32B
est: 1.50B (-12.2%)
|
1.77B
est: 1.92B (-7.8%)
|
2.06B
2.01B – 2.11B
+7.7% YoY
|
2.29B
2.16B – 2.38B
+11.0% YoY
|
2.52B
2.50B – 2.53B
+9.8% YoY
|
| EBIT |
4.51B
est: 2.23B (+102.4%)
|
1.38B
est.
|
1.49B
est: 1.90B (-21.3%)
|
1.97B
est: 1.06B (+85.8%)
|
814.27M
est: 1.06B (-23.3%)
|
966.42M
est: 1.18B (-17.9%)
|
1.10B
est: 1.51B (-26.7%)
|
1.62B
1.58B – 1.65B
+7.7% YoY
|
1.80B
1.70B – 1.87B
+11.0% YoY
|
1.98B
1.97B – 1.98B
+9.8% YoY
|
| Net Income |
3.81B
est: 3.74B (+1.9%)
|
1.28B
est.
|
1.24B
est: 1.68B (-26.2%)
|
1.65B
est: 282.94M (+483.4%)
|
580.40M
est: 282.94M (+105.1%)
|
695.38M
est: 803.23M (-13.4%)
|
767.97M
est: 1.04B (-26.2%)
|
1.02B
891.53M – 1.03B
-1.6% YoY
|
1.20B
1.04B – 1.22B
+16.7% YoY
|
1.41B
1.20B – 1.42B
+18.1% YoY
|
| SGA |
2.01B
est: 3.58B (-43.8%)
|
2.21B
est.
|
2.44B
est: 3.05B (-19.9%)
|
2.65B
est: 2.15B (+22.9%)
|
2.76B
est: 2.15B (+27.9%)
|
2.93B
est: 2.39B (+22.7%)
|
1.69B
est: 3.05B (-44.7%)
|
3.29B
3.21B – 3.36B
+7.7% YoY
|
3.65B
3.44B – 3.79B
+11.0% YoY
|
4.01B
3.99B – 4.03B
+9.8% YoY
|
| EPS |
7.00
est: 6.40 (+9.4%)
|
2.19
est.
|
2.08
est: 2.88 (-27.7%)
|
2.79
est: 0.48 (+482.6%)
|
0.98
est: 0.48 (+104.7%)
|
1.19
est: 1.41 (-15.7%)
|
1.32
est: 1.80 (-26.7%)
|
1.69
1.53 – 1.77
-6.3% YoY
|
1.95
1.79 – 2.10
+15.2% YoY
|
2.21
2.07 – 2.45
+13.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck ChiNext ETF CNXT | 0.07% | 89.7K | 0.65% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.06% | 23.0K | 0.65% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 124.8K | 0.19% |
| 4 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.00% | 2.7K | 0.15% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 53.1K | 0.46% |
| 6 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 13.0K | 0.40% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 189.7K | 0.39% |
| 8 | Vanguard International High Dividend Yield ETF VYMI | 0.00% | 322.8K | 0.07% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 44.6K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.8K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guan Lai Liao | Deputy General Manager | — | male |
| Huixuan Chen | Deputy GM & Secretary | — | female |
| Jianquan Li | Chairman, CEO & GM | — | male |
| Liao Meizhen | Non-Independent Director | — | female |
| Xia Yan | Deputy General Manager | — | female |
| Xiuyuan Fang | Non-Independent Director, Deputy GM & Chief Financial Officer | — | male |
| Yan Zhao | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300888.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
